Can coenzyme Q10 supplementation effectively reduce human tumor necrosis factor-α and interleukin-6 levels in chronic inflammatory diseases? A systematic review and meta-analysis of randomized controlled trials

Effects of coenzyme Q10 on health-related quality of life, clinical disease activity and blood pressure in patients with mild to moderate ulcerative colitis: a randomized clinical trial

“…Moreover, CoQ10, as a potent lipophilic antioxidant could be neutralized harmful free radical species in lipid and mitochondrial membranes and regenerated several antioxidants ( 33 , 34 ). A part of the beneficial effects observed by CoQ10 might be related to its anti-inflammatory properties on the immune-inflammatory cytokines such as tumor necrosis factor-alpha and inteleukin-6 via down-regulating nuclear factor NF-κB-dependent gene expression and -activation by the ROS according to the present and previous studies ( 35 , 36 ). Furthermore, it should be mentioned that both oxidative stress and excessive expression of inflammatory cytokines as major causes have involved in the pathogenic pathway of UC which, in turn, encouraged the use of antioxidant compounds with anti-inflammatory properties ( 22 ).…”

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases

“…Inflammation is considered a main process involved in atherosclerosis development [74]. A recent meta-analysis of nine RCTs and 509 patients showed that the CoQ 10 supplementation in chronic inflammatory diseases (60-500 mg/day for 8-12 weeks) is responsible for the significant reduction in the plasma levels of tumor necrosis factor alpha (TNF-α) (SMD: −0.44, 95% CI: (−0.81 to −0.07) mg/dl; I 2 = 66.1%, p < 0.01) and in IL-6 levels (SMD: −0.37, 95% CI: (−0.65 to −0.09), p = 0.01) [75]. Similar results were obtained by the metanalysis of Fan et al that demonstrated a reduction of the C-reactive protein levels in addition to the abovementioned parameters in patients afflicted by inflammatory diseases [76]; in elderly people with low CoQ 10 levels; and in patients with metabolic diseases characterized by chronic, low grade inflammation [17].…”

Coenzyme Q10 Supplementation Improves Adipokine Levels and Alleviates Inflammation and Lipid Peroxidation in Conditions of Metabolic Syndrome: A Meta-Analysis of Randomized Controlled Trials

“…Beyond its impact on lipid peroxidation, published evidence from randomized clinical trials (RCTs) shows that CoQ 10 remains important in ameliorating inflammation and improving adipokine function in conditions of metabolic syndrome [25][26][27]. Although other meta-analysis of RCTs has been conducted on the effects of CoQ 10 on markers of inflammation or oxidative stress [28][29][30], including assessing adiponectin levels [31], such information remains limited for being too specific and does not collectively give a better picture on the influence of this quinone on conditions of metabolic syndrome. Therefore, this meta-analysis assesses essential evidence on the modulatory effects of CoQ 10 on adipokine function, including its impact on markers of inflammation and lipid peroxidation in individuals with metabolic syndrome.…”